To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

JW Pharmaceutical

Status and phase: Completed; Phase 3

Conditions: Hypertension; Dyslipidemia

Treatments: Drug: VA; Drug: LivaloVA; Drug: LivaloV

Study type: Interventional

Funder types: Industry

Identifiers

NCT05331014

JWP-PVA-301

Details and patient eligibility

About

A Multi-center, Randomized, Double-blind, Parallel, phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients with Dyslipidemia and Hypertension.

Full description

Multicenter, randomized, double-blind, parallel-design, phase III clinical study

Enrollment: 155 patients

Sex: All

Ages: 19 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hypertension and dyslipidemia

Exclusion criteria

• The subject not meet the specified msBP and LDL-C level

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

155 participants in 3 patient groups

JW0101+C2101

Experimental group

Description:

LivaloVA

Treatment:

Drug: LivaloVA

JW0101+C2102

Active Comparator group

Description:

LivaloV

Treatment:

Drug: LivaloV

C2101

Active Comparator group

Description:

VA

Treatment:

Drug: VA